|
Age
|
71 [61–88]
|
|
Pretherapeutic PSA value [ng/ml]
|
591 [14–3277]
|
|
Pretherapeutic ECOG PSa
|
|
0
|
7 (29.2%)
|
|
1
|
16 (66.7%)
|
|
2
|
1 (4.2%)
|
|
Previous treatments
|
|
Prostatectomy
|
11 (45.8%)
|
|
Radiation
|
15 (62.5%)
|
|
Androgen deprivation therapy
|
24 (100%)
|
|
Enzalutamide or abiraterone
|
23 (95.8%)
|
|
Enzalutamide
|
20 (83.3%)
|
|
Abiraterone
|
22 (91.7%)
|
|
Enzalutamide and abiraterone
|
19 (79.2%)
|
|
Chemotherapy
|
19 (79.2%)
|
|
Docetaxel
|
19 (79.2%)
|
|
Cabazitaxel
|
8 (33.3%)
|
|
Docetaxel and cabazitaxel
|
8 (33.3%)
|
|
223Ra therapy
|
8 (33.3%)
|
|
153Sm therapy
|
1 (4.2%)
|
|
Sites of metastases
|
|
Bone
|
24 (100%)
|
|
Lymph node
|
18 (75%)
|
|
Other
|
10 (41.7%)
|
|
Tumor load according to [25]
|
|
High
|
11 (45.8%)
|
|
Medium
|
13 (54.2%)
|
|
Low
|
0 (0 %)
|
